Therefore, pharmacologically inhibiting oncogenic KRAS signaling has been suggested for a long time and is still considered as the “Holy Grail” in the quest for targeted therapeutic approaches directed against pancreatic cancer by many authors [19]. Here, KRAS is linked to familial pancreatic carcinoma.